Based on the clinical trial information, PD-L1 expression, tumor mutation burden (TMB), microsatellite instability-high (MSI-H) and mismatch-repair deficiency (MMR) have been identified as predictive biomarkers for anti-PD-1/PD-L1 antibody therapies[107,108,109,110,111]. Although biomarkers of...
Epacadostat is an IDO1 selective inhibitor, which is the most advanced in the clinical development and would be supposed to be the first IDO1 inhibitor to get registration approval. Epacadostat showed preliminary promising anti-cancer activity in its early phase I/II trials (ECHO-202/KEYNOTE-...
In the case of lung-specific oligometastatic CRC, analysis of primary and metastatic tumors reveals a decrease in the tumor mutation burden (TMB), regressive mutations in K-Ras, and SMAD4, and scarce T cell infiltrate. A point mutation in ERBB2 (a member of tyrosine kinase receptor) which ...